secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2026-08-24T21:13:36+00:00
Accession:  0001493152-26-039898
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensyce raises $21M initial tranche of $43M Series C financing; Nasdaq compliance update
--------------------------------------------------------------------------------

- Initial closing Aug 7, 2026 raised >$21M gross; issued 120,260 Series C preferred shares.
- Two-tranche $43M Securities Purchase Agreement; second tranche closes on clinical milestone.
- Company believes it satisfies Nasdaq's $2.5M minimum stockholders' equity (Rule 5550(b)(1)).
- Requested Aug 24, 2026 for second 180-day grace period on $1.00 bid price rule (equity >=$5M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226039898/0001493152-26-039898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226039898/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-039898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer